Female Sexual Dysfunction - Results from Datamonitor's 2005 physician survey

Patients in a clinical population receive drug and non-drug therapy for female sexual dysfunction, yet a third remain refractory to treatment, highlighting a need for a formally approved product for FSD. There is a low level of satisfaction with the classification guidelines, further limiting diagnosis, already hampered by embarrassment, lack of physician awareness and an unclear referral system.

Testosterone therapies are already widely used among women with hypoactive sexual desire disorder and female sexual arousal disorder. There is a significant market for a formally approved testosterone product for women, with 85% of prescribers willing to switch existing testosterone users onto an approved product.

There is a distinct need for more specialized services in support of those with sexual functioning problems. There is no clear referral pathway for primary care physicians and no specialist service for patients to present directly to. This causes a barrier to presentation, diagnosis and treatment.

The identification and classification of FSD is biased by physician's perception. A woman presenting with sexual difficulties could receive a variety of diagnoses or even no diagnosis at all. There is a need not only for a more holistic approach to sexual dysfunction, but also for validated and consistent tools to assess and diagnose patients.

Read more...

• Female Sexual Dysfunction (20/05/2008)

• Supportive Care in Oncology (21/05/2008)
• Irritable Bowel Syndrome (21/05/2008)
• Monoclonal Antibodies (21/05/2008)
• Depression (21/05/2008)
• Insomnia (21/05/2008)
• Multiple Sclerosis (21/05/2008)
• Osteoporosis (21/05/2008)
• Monoclonal Antibodies (20/05/2008)
• Top 20 Cancer Therapy Brands (20/05/2008)

---